Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of MHB036C injection in combination with other anticancer therapies for advanced lung cancer
CTR20250168Phase 2Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MHB036C in bronchial carcinoma, sponsored by Minghui Pharmaceutical, Inc.. Started Jan 2025; status: active.
02
Drugs
MHB036C
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on CTR20250168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250168.